Metamizol for the Treatment of Neoplastic Chronic Pain

Pain Clinical Trial

Official title:

Analgesic Effect of a New Metamizol Oral Pharmaceutical Form for the Treatment of the Neoplastic Chronic Pain: Randomized, Double-blind Crossover Clinical Trial Between Metamizol, Diclofenac and Placebo

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02181920
• Other study ID #: 1093.14
• Status: Terminated
• Phase: Phase 4
• First received: July 2, 2014
• Last updated: July 17, 2014
• Start date: March 2000

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

Study to evaluate the efficacy of metamizole in reducing morphine requirements in patients with moderate to severe chronic cancer pain in comparison to administration of placebo or diclofenac.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. primary completion date: November 2000
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hospitalized patients with neoplastic chronic pain requiring morphine treatment

Exclusion Criteria:

• Karnofsky index less than 30%

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Pain
• Pain

Intervention

Drug:
• Metamizole

• Diclofenac

• Diclofenac placebo

• Metamizole placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in morphine requirement		Baseline, 9 days	No

External Links

•   Link